Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies

NCT06028074 is registered in ClinicalTrials.gov with Georgiamune Inc as lead sponsor.

NCT NCT06028074
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06028074 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-Human, Open-Label, Phase 1/2 Dose-Escalation With Enrichment and Dose-Expansion Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Antitumor Activity of GIM-122 as a Single Agent in Adult Subjects With Advanced Solid Malignancies
Lead sponsor
Georgiamune Inc
Phase
Phase 1/2
Overall status
Recruiting
Start date
December 12, 2023
Completion date
December 31, 2026
Enrollment
111 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies